A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Decitabine (Primary) ; Pevonedistat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 06 Jul 2017 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.
- 06 Jul 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jul 2019.
- 06 Jul 2017 Status changed from not yet recruiting to recruiting.